MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin.
Emeline BollaertMelissa ClausVirginie VandewalleSandrine LenglezAhmed EssaghirJean-Baptiste DemoulinViolaine HavelangePublished in: International journal of molecular sciences (2021)
Anthracyclines remain a cornerstone of induction chemotherapy for acute myeloid leukemia (AML). Refractory or relapsed disease due to chemotherapy resistance is a major obstacle in AML management. MicroRNAs (miRNAs) have been observed to be involved in chemoresistance. We previously observed that miR-15a-5p was overexpressed in a subgroup of chemoresistant cytogenetically normal AML patients compared with chemosensitive patients treated with daunorubicin and cytarabine. MiR-15a-5p overexpression in AML cells reduced apoptosis induced by both drugs in vitro. This study aimed to elucidate the mechanisms by which miR-15a-5p contributes to daunorubicin resistance. We showed that daunorubicin induced autophagy in myeloid cell lines. The inhibition of autophagy reduced cell sensitivity to daunorubicin. The overexpression of miR-15a-5p decreased daunorubicin-induced autophagy. Conversely, the downregulation of miR-15a-5p increased daunorubicin-induced autophagy. We found that miR-15a-5p targeted four genes involved in autophagy, namely ATG9a, ATG14, GABARAPL1 and SMPD1. Daunorubicin increased the expression of these four genes, and miR-15a-5p counteracted this regulation. Inhibition experiments with the four target genes showed the functional effect of miR-15a-5p on autophagy. In summary, our results indicated that miR-15a-5p induces chemoresistance in AML cells through the abrogation of daunorubicin-induced autophagy, suggesting that miR-15a-5p could be a promising therapeutic target for chemoresistant AML patients.
Keyphrases
- acute myeloid leukemia
- endoplasmic reticulum stress
- cell death
- induced apoptosis
- signaling pathway
- cell cycle arrest
- oxidative stress
- diabetic rats
- allogeneic hematopoietic stem cell transplantation
- end stage renal disease
- high glucose
- ejection fraction
- newly diagnosed
- cell proliferation
- chronic kidney disease
- squamous cell carcinoma
- randomized controlled trial
- low dose
- poor prognosis
- peritoneal dialysis
- genome wide
- diffuse large b cell lymphoma
- pi k akt
- clinical trial
- transcription factor
- bone marrow
- gene expression
- drug delivery
- locally advanced
- endothelial cells
- single cell
- stem cells
- dendritic cells
- radiation therapy
- stress induced
- rectal cancer
- binding protein
- patient reported